RT Journal Article
SR Electronic
T1 Antiretroviral therapy retention, adherence, and clinical outcomes among postpartum women with HIV in Nigeria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.17.24305982
DO 10.1101/2024.04.17.24305982
A1 Young, Clara M.
A1 Chang, Charlotte A.
A1 Sagay, Atiene S.
A1 Imade, Godwin
A1 Ogunsola, Olabanjo O.
A1 Okonkwo, Prosper
A1 Kanki, Phyllis J.
YR 2024
UL http://medrxiv.org/content/early/2024/04/22/2024.04.17.24305982.abstract
AB While research involving pregnant women with HIV has largely focused on the antepartum and intrapartum periods, few studies in Nigeria have examined the clinical outcomes of these women postpartum. This study aimed to evaluate antiretroviral therapy retention, adherence, and viral suppression among postpartum women in Nigeria. This retrospective clinical data analysis included women with a delivery record at the antenatal HIV clinic at Jos University Teaching Hospital between 2013 and 2017. Descriptive statistics quantified proportions retained, adherent (≥95% medication possession ratio), and virally suppressed up to 24 months postpartum. Among 1535 included women, 1497 met the triple antiretroviral therapy eligibility criteria. At 24 months, 1342 (89.6%) women remained in care, 51 (3.4%) reported transferring, and 104 (7.0%) were lost to follow-up. The proportion of patients with ≥95% medication possession ratio decreased from 79.0% to 69.1% over the 24 months. Viral suppression among those with results was 88.7% at 24 months, but <62% of those retained had viral load results at each time point. In multiple logistic regression, predictors of loss to follow-up included having a more recent HIV diagnosis, higher gravidity, fewer antenatal care visits, and a non-hospital delivery. Predictors of viral non-suppression included poorer adherence, unsuppressed/missing baseline viral load, lower baseline CD4+ T-cell count, and higher gravidity. Loss to follow-up rates were lower and antiretroviral therapy adherence rates similar among postpartum women at our study hospital compared with other sub-Saharan countries. Longer follow-up time and inclusion of multiple facilities for a nationally representative sample would be beneficial in future studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the APIN Public Health Initiatives and Harvard T.H. Chan School of Public Health Institutional Review Boards (IRB20-1102). Data used were from patients who provided written informed consent for the use of their data for secondary research at the time of enrollment in the HIV program, and were de-identified before analyses.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData cannot be shared publicly because of confidentiality and ethical restrictions associated with patient data collected in a clinical care program. The data that support the findings of this study are available on request from the corresponding author with permission from the APIN Public Health Initiatives Institutional Review Board, Abuja, Nigeria.